Remove keyword pfizer
article thumbnail

Grand Rounds September 29, 2023: Navigating the Use of Patient-Reported Outcomes in Research and Practice: The PROTEUS Consortium (Claire Snyder, PhD; Norah Crossnohere, PhD; Anne Schuster, PhD)

Rethinking Clinical Trials

PROTEUS and Pfizer partnered to form an Advisory Group that aimed to improve understanding of the facilitators and barriers of implementing routine PRO assessments in vulnerable and underserved populations and build capacity for PRO implementation to improve care for cancer patients who are vulnerable or underserved.

article thumbnail

Grand Rounds October 27, 2023: Digital, Decentralized and Democratized: Lessons From The Yale PaxLC Trial (Harlan M. Krumholz, MD, SM)

Rethinking Clinical Trials

Pfizer provided feedback. Can you comment on the decision to make the PROMIS scale the primary outcome? Does it capture most what matters to patients? We spent a lot of time discussing what would be the best primary outcome. We wanted to measure a lot of stuff. We wanted to say if this is working, people’s general health should improve.

Trials 228